CLINICAL AND EPIDEMIOLOGICAL FEATURES OF PAPILLOMAVIRUS INFECTION MANIFESTATIONS ON THE EXAMPLE OF CERVICAL CANCER AND GENITAL WARTS

  • Authors: Briko N.1,2, Sekacheva M.1, Lopukhov P.1, Kobzev G.1, Kaprin A.3, Novikova E.3, Trushina O.3, Khaldin A.4, Maleev V.2
  • Affiliations:
    1. I.M. Sechenov First Moscow State Medical University (Sechenov University)
    2. Central Research Institute for Epidemiology
    3. P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia
    4. Moscow Scientific and Practical Center of Dermato-Venereology and Cosmetology
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/1212
  • DOI: https://doi.org/10.15690/vramn1212
Open Access Open Access
Restricted Access Subscription or Fee Access

Abstract


Background: cervical cancer and genital warts (GWs) are some of the most common manifestations of human papillomavirus infection (HPV). These lesions cause significant damage to the reproductive health of the population, which leads to increasing attention in recent years to the prevention of HPV infection among various population groups.

Aims: To determine the clinical and epidemiological features of the HPV manifestations by the example of cervical cancer and genital warts.

Materials and methods: A retrospective analysis of anamnestic information of 115 women with an established diagnosis of cervical cancer and 177 patients with an established diagnosis of GWs was performed. The clinical and epidemiological characteristics of patients with diagnoses of GWs and cervical cancer were based on the development of outpatient admission cards and inpatient histories, as well as test data for HPV.

Results: HPV 16 was the most common HPV type among patients with GWs and cervical cancer –  it was detected in 37.6% of cases. Also the most frequently encountered: HPV 6 / 18 / 11 / 31 / 51 / 52. In 43.2% cases of HPV detection, two or more types were detected at once, the most common combinations: HPV 16 and HPV 18, HPV 6 and HPV 16, HPV 6 and HPV 11. Analysis of the frequency of screening for cervical cancer and visits to the gynecologist for 5 years before establishing the diagnosis showed that among those who did not screen for cervical cancer, the risk of diagnosing stage II–IV was 5.2 times higher than among individuals who underwent cervical screening 2 years ago, or once a year for the last five years. Among patients with GWs who had 2 or more sexual partners for 1 year, 13.5% of patients regularly used barrier contraception methods (condoms) during sexual contact, not regularly – 61.5%, did not use them at all – 25.0%.

Conclusions: Identifying the clinical and epidemiological features of HPV infection should contribute to the development of new and optimize existing prevention programs for a wide range of HPV-associated diseases.


Nikolay Briko

I.M. Sechenov First Moscow State Medical University (Sechenov University); Central Research Institute for Epidemiology

Email: nbrico@mail.ru
ORCID iD: 0000-0002-6446-2744
SPIN-code: 2992-6915
Scopus Author ID: 7004344976

Russian Federation, 119991, Москва, ул. Трубецкая, д. 8, стр. 2; 111123, Москва, ул. Новогиреевская, д. 3а

заслуженный деятель науки РФ, академик РАН, д.м.н., профессор, директор Института общественного здоровья, заведующей кафедрой эпидемиологии и доказательной медицины ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет), Ведущий научный сотрудник Центрального научно-исследовательского института эпидемиологии Роспотребнадзора

Marina Sekacheva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: sekach_rab@mail.ru
SPIN-code: 4801-3742
Scopus Author ID: 24342526600

Russian Federation, 119991, Москва, ул. Трубецкая, д. 8, стр. 2

д.м.н., профессор, проректор по научно-исследовательской работе

Platon Lopukhov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: PL2211@yandex.ru
ORCID iD: 0000-0002-0872-2214
SPIN-code: 1250-6839
Scopus Author ID: 57191340780
ResearcherId: S-8582-2017

Russian Federation, 119991, Москва, ул. Трубецкая, д. 8, стр. 2

к.м.н., старший преподаватель кафедры эпидемиологии и доказательной медицины

Gleb Kobzev

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: glebk09@mail.ru

Russian Federation, 119991, Москва, ул. Трубецкая, д. 8, стр. 2

ординатор кафедры эпидемиологии и доказательной медицины

Andrey Kaprin

P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia

Email: mnioi@mail.ru
ORCID iD: 0000-0001-8784-8415
SPIN-code: 1759-8101
Scopus Author ID: 6602709853

Russian Federation, 125284, г. Москва, 2-й Боткинский пр., д. 3

академик РАН, член-корр. РАО, д.м.н., профессор, Директор

Elena Novikova

P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia

Email: mnioi@mail.ru
ORCID iD: 0000-0003-2768-5698
SPIN-code: 2143-9975
Scopus Author ID: 7102446296

Russian Federation, 125284, г. Москва, 2-й Боткинский пр., д. 3

заслуженный деятель науки РФ, д.м.н., профессор, руководитель отделения онкогинекологии

Olga Trushina

P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia

Email: o.trushina@list.ru
SPIN-code: 9885-3814
Scopus Author ID: 6506506500

Russian Federation, 125284, г. Москва, 2-й Боткинский пр., д. 3

д.м.н., старший научный сотрудник онкогинекологического отделения

Aleksey Khaldin

Moscow Scientific and Practical Center of Dermato-Venereology and Cosmetology

Email: khaldinderma@yandex.ru
ORCID iD: 0000-0002-3855-1655
Scopus Author ID: 7801322925

Russian Federation, 127473 Москва, ул. Селезневская, д. 20

д.м.н., профессор, член-корреспондент РАЕН, главный научный сотрудник

Victor Maleev

Central Research Institute for Epidemiology

Email: crie@pcr.ru
ORCID iD: 0000-0001-5748-178X
SPIN-code: 1712-9809
Scopus Author ID: 7006690997

Russian Federation, 111123, Москва, ул. Новогиреевская, д. 3а

академик РАН, доктор медицинских наук, профессор, советник директора по научной работе

  • de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15;141(4):664–670. doi: 10.1002/ijc.30716.
  • Брико Н.И., Лопухов П.Д., Каприн А.Д. и др. ВПЧ-ассоциированные поражения в Российской Федерации: оценка состояния проблемы. Современная онкология. 2019; 21 (1): 45–50. [Briko NI, Lopukhov PD, Kaprin AD, et al. HPV-associated lesions in the Russian Federation: assessment of the problem. Journal of Modern Oncology. 2019;21(1):45–50. (In Russ.).] doi: 10.26442/18151434.2019.190199.
  • Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГУ «НМИРЦ» Минздрава России, 2018. 250 с. [Kaprin A.D., Starinskij V.V., Petrova G.V. Zlokachestvennye novoobrazovanija v Rossii v 2017 godu (zabolevaemost' i smertnost') [Malignancies in Russia in 2017 (morbidity and mortality)]. Moscow: Moskovskiy nauchno-issledovatel'skiy onkologicheskiy institut im. P.A. Gertsena – filial FGU «NMIRС» Minzdrava Rossii, 2018. 250 p. (In Russ.).]
  • Barchuk A, Bespalov A, Huhtala H, et al. Breast and cervical cancer incidence and mortality trends in Russia 1980–2013. Cancer Epidemiol. 2018 Aug;55:73–80. doi: 10.1016/j.canep.2018.05.008.
  • Fairley CK, Donovan B. What can surveillance of genital warts tell us? Sex Health 2010;7(3):325–7. doi: 10.1071/SH09145.
  • Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013 Jan 25;13:39. doi: 10.1186/1471-2334-13-39.
  • Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019.
  • Simms KT Steinberg J Caruana M et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol. 2019;20:394–407. doi: 10.1016/S1470-2045(18)30836-2.
  • Hall MT Simms KT Lew J-B et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4:19–27. doi: 10.1016/S2468-2667(18)30183-X.
  • Зароченцева Н.В., Белая Ю.М. Опыт реализации программ первичной профилактики заболеваний, вызываемых вирусом папилломы человека, в Московской области. Эпидемиология и Вакцинопрофилактика. 2017;16(6):59–65 [Zarochentseva NV, Belaiya JM. Experience in the Implementation of Programs for Primary Prevention of Human Papillomavirus-associated Diseases in the Moscow region). Epidemiology and Vaccinal Prevention. 2017;16(6):59–65. (In Russ.).] doi: 10.31631/2073-3046-2017-16-6-59-65.
  • Каприн А.Д., Новикова Е.Г., Трушина О.И., Грецова О.П. Cкрининг рака шейки матки – нерешенные проблемы. Исследования и практика в медицине. 2015;2(1):36–41. [Kaprin AD, Novikova EG, Trushina OI, Gretzova OP. The cervical cancer screening – unsolved problems. Research'n Practical Medicine Journal. 2015;2(1):36–41. (In Russ.).] doi: 10.17709/2409-2231-2015-2-1-36-41.
  • Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006 Jun 22;354(25):2645–54. doi: 10.1056/NEJMoa053284.

Views

Abstract - 22

PDF (Russian) - 0

PDF (Russian) - 0

PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies